Interim results for the six months ended 30 June 2021
Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group,…
Notice of Interim Results
London, UK – 1 September 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June…
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden…
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…
Oxford Biomedica 2020 Annual Report and Accounts & AGM Notification
London, UK – 27 April 2021: Oxford Biomedica plc (“Oxford Biomedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the…
Preliminary results for the year ended 31 December 2020
Oxford Biomedica plcPreliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading…
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors
Oxford, UK – 6 April, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new…
Board Changes
Oxford, UK – 3 February, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces two changes to the Group’s Board…
Prime Minister Boris Johnson formally opens Oxford Biomedica’s manufacturing facility Oxbox
Oxford, UK – 18 January, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today that the Prime Minister Rt Hon…
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK
Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) has announced that their…
John Dawson named Executive of the Year for Companies <$10bn at the Annual Scrip Awards 2020
-Ends- Oxford, UK – 3 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, John Dawson,…
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary…